FDA inspection
Unither Manufacturing LLC.: FDA inspection ending Dec 8, 1999
FDA inspection 7146 · No Action Indicated (NAI) · Rochester, NY
Key facts
| Inspection ID | 7146 |
|---|---|
| Firm | Unither Manufacturing LLC. |
| FEI number | 1314625 |
| Address | 755 Jefferson Rd |
| City | Rochester |
| State | NY |
| ZIP | 14623-3233 |
| Fiscal year | 2000 |
| Inspection end date | Dec 8, 1999 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data